Terra pharmaceutica - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 219,820 | 264,052 | 259,376 | 386,506 | 515,543 | 295,247 | 335,574 | 183,568 |
| Profit before tax | -52,392 | -34,909 | -7,788 | 791 | -25,117 | -51,228 | -62,251 | -43,971 |
| Net profit | -52,392 | -34,909 | -7,788 | 500 | -25,117 | -51,228 | -62,251 | -43,971 |
| Equity | -35,311 | -20,207 | -27,994 | 11,023 | -14,094 | -65,322 | -127,573 | -171,544 |
| Liabilities | 150,347 | 151,651 | 206,689 | 207,340 | 141,519 | 246,812 | 384,667 | 407,278 |
| Non-current assets | 11,818 | 8,959 | 2,111 | 2,647 | 2,847 | 1,475 | 1,259 | 771 |
| Current assets | 101,493 | 120,764 | 175,023 | 213,211 | 122,193 | 178,122 | 248,644 | 188,548 |
| Total assets | 113,311 | 129,723 | 177,134 | 215,858 | 125,040 | 179,597 | 249,903 | 189,319 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 45,375 | 23,485 | 30,787 |
| Social insurance contributions | - | - | - | - | - | - | 5,505 | 6,717 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -20.0% | +20.1% | -1.8% | +49.0% | +33.4% | -42.7% | +13.7% | -45.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -46.2% | -26.9% | -4.4% | 0.2% | -20.1% | -28.5% | -24.9% | -23.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 4.5% | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -23.8% | -13.2% | -3.0% | 0.1% | -4.9% | -17.4% | -18.6% | -24.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -23.8% | -13.2% | -3.0% | 0.2% | -4.9% | -17.4% | -18.6% | -24.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 18.8 | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 65,947 | 83,384 | 111,163 | 193,253 | 193,326 | 90,845 | 83,894 | 55,071 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Terra pharmaceutica - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-23 | 2026-07-26 | 1.04 |
| 2026-06-16 | 2026-06-18 | 280.71 |
| 2026-05-17 | 2026-05-17 | 914.70 |
| 2025-06-17 | 2025-06-19 | 26.70 |
| 2025-06-11 | 2025-06-15 | 26.70 |
| 2025-06-08 | 2025-06-09 | 26.70 |
| 2025-05-16 | 2025-06-04 | 26.70 |
| 2024-01-16 | 2024-02-13 | 68.47 |
| 2023-12-18 | 2024-01-11 | 176.47 |
| 2023-11-16 | 2023-12-11 | 212.47 |
| 2023-11-14 | 2023-11-14 | 212.47 |
| 2023-10-17 | 2023-11-13 | 248.47 |
| 2023-09-18 | 2023-10-01 | 284.47 |
| 2023-09-14 | 2023-09-14 | 284.47 |
| 2023-08-17 | 2023-09-13 | 320.47 |
| 2023-08-14 | 2023-08-15 | 320.47 |
| 2023-07-18 | 2023-08-13 | 356.47 |
| 2023-06-16 | 2023-07-13 | 392.47 |
| 2023-05-16 | 2023-06-12 | 428.47 |
| 2023-05-12 | 2023-05-14 | 428.47 |
| 2023-05-02 | 2023-05-11 | 464.47 |
| 2023-04-18 | 2023-04-28 | 464.47 |
| 2023-04-14 | 2023-04-16 | 464.47 |
| 2023-03-16 | 2023-04-13 | 500.47 |
| 2023-02-17 | 2023-03-12 | 536.47 |
| 2023-02-14 | 2023-02-14 | 536.47 |
| 2023-02-06 | 2023-02-13 | 572.47 |
| 2023-01-17 | 2023-02-03 | 572.47 |
| 2023-01-06 | 2023-01-12 | 572.47 |
| 2022-12-16 | 2023-01-05 | 608.47 |
| 2022-12-14 | 2022-12-14 | 608.47 |
| 2022-11-21 | 2022-12-13 | 644.47 |
| 2022-11-17 | 2022-11-18 | 644.47 |
| 2022-11-11 | 2022-11-13 | 31.59 |
| 2022-10-18 | 2022-11-10 | 680.47 |
| 2022-10-14 | 2022-10-17 | 31.49 |
| 2022-10-13 | 2022-10-13 | 67.49 |
| 2022-09-16 | 2022-10-12 | 716.47 |
| 2022-09-14 | 2022-09-15 | 66.41 |
| 2022-09-07 | 2022-09-13 | 102.41 |
| 2022-08-23 | 2022-09-06 | 752.47 |
| 2022-08-12 | 2022-08-15 | 752.47 |
| 2022-07-26 | 2022-08-11 | 788.47 |
| 2022-07-18 | 2022-07-25 | 2364.04 |
| 2022-07-14 | 2022-07-17 | 788.47 |
| 2022-06-16 | 2022-07-13 | 824.47 |
| 2022-06-07 | 2022-06-13 | 13.22 |
| 2022-05-17 | 2022-06-06 | 860.47 |
| 2022-05-13 | 2022-05-16 | 91.07 |
| 2022-05-10 | 2022-05-12 | 127.07 |
| 2022-04-19 | 2022-05-09 | 896.47 |
| 2022-04-14 | 2022-04-14 | 896.47 |
| 2022-03-16 | 2022-04-13 | 932.47 |
| 2022-03-15 | 2022-03-15 | 252.80 |
| 2022-03-14 | 2022-03-14 | 932.47 |
| 2022-02-17 | 2022-03-13 | 968.47 |
| 2022-02-14 | 2022-02-16 | 191.92 |
| 2022-02-11 | 2022-02-13 | 227.92 |
| 2022-01-18 | 2022-02-10 | 1004.47 |
| 2022-01-14 | 2022-01-17 | 251.07 |
| 2021-12-16 | 2022-01-13 | 1040.47 |
| 2021-12-10 | 2021-12-15 | 363.88 |
| 2021-12-06 | 2021-12-09 | 399.88 |
| 2021-11-16 | 2021-12-05 | 1076.47 |
| 2021-11-15 | 2021-11-15 | 399.88 |
| 2021-10-18 | 2021-11-14 | 1112.47 |
| 2021-10-14 | 2021-10-17 | 368.34 |
| 2021-10-13 | 2021-10-13 | 404.34 |
| 2021-10-04 | 2021-10-12 | 1148.47 |
| 2021-09-16 | 2021-10-03 | 1151.47 |
Terra pharmaceutica - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-27 | 2026-03-02 | 0.08 |
| 2026-02-21 | 2026-02-26 | 179.5 |
| 2025-01-22 | 2025-01-27 | 5.3 |
| 2025-01-15 | 2025-01-21 | 543.98 |
| 2024-12-14 | 2024-12-15 | 628.21 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Terra pharmaceutica, UAB (code 303437022) is a private limited liability company engaged in the wholesale of perfume and cosmetics. In 2025, the company generated revenue of €183.6K, down 45.3% year on year and 37.8% below the 2023 level. Net loss was €44.0K, which still meant a negative profit margin of 24.0%, although the loss was smaller than in 2024, when revenue reached €335.6K and the net loss was €62.3K. The 2023 result was also negative at €51.2K. Over the three-year period, revenue rose in 2024 before falling sharply in 2025, while losses remained persistent. The balance sheet weakened further: total assets declined to €189.3K in 2025 from €249.9K in 2024, equity deepened to minus €171.5K, and liabilities increased to €407.3K. The reported return on assets was negative, while return on equity and debt-to-equity should be interpreted cautiously because equity was negative. Asset turnover was 0.97x. Revenue per employee was €61.2K, while profit per employee was negative.